IP Library Granted Patent US 12,515,044
Granted Patent B2
US 12,515,044 · App. 18/426,800 · Granted Jan 6, 2026

Using power loss density and related measures to quantify the dose of tumor treating fields (TTFields)

Inventors: Zeev Bomzon (Haifa, IL); Hadas Sara Hershkovich (Haifa, IL); Noa Urman (Haifa, IL); Ariel Naveh (Haifa, IL); Shay Levi (Haifa, IL)
Assignee: Novocure GmbH
A61N1/36002G16H30/40A61B5/055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,515,044
App. No.
18/426,800
Granted
Jan 6, 2026
Kind
B2
Abstract

The planning of treatment using tumor treating fields (TTFields) in a portion of a subject's body (e.g., the subject's head) can be improved by obtaining an image of the body portion, and generating, based on the image, a 3D model of electrical conductivity. A target volume within the 3D model is identified, and a set of model electrodes is added to the 3D model at given locations. Then, for each voxel in the target volume, the power loss density (PLD) that will be present when TTFields are eventually applied is determined. The same process is repeated for a plurality of different electrode locations. Finally, the set of electrode locations that yielded the best PLD is selected, and a description of those locations is output.

Claims (19)

1 . A method of planning a treatment using alternating electric fields at a given frequency in a portion of a subject's body, the method comprising the steps of:

(a) obtaining at least one image of the portion;

(b) generating, based on the obtained at least one image, a 3D model of electrical conductivity or resistivity at the given frequency within the portion;

(c) identifying a target volume within the 3D model, the target volume including a plurality of voxels;

(d) adding a first set of model electrodes to the 3D model, with the first set of model electrodes positioned at a first set of locations with respect to the 3D model; and

(e) determining, for each of the voxels in the target volume, a power loss density that will be present when the first set of model electrodes positioned at the first set of locations is used to impose an alternating electric field in the target volume,

wherein step (e) comprises (i) determining, for each of the voxels in the target volume, an electric field intensity that will be present when a respective set of model electrodes positioned at a respective set of locations is used to impose an alternating electric field in the target volume, and (ii) determining a respective power loss density for each voxel in the target volume based on the conductivity of the 3D model at the voxel and the electric field intensity at the voxel.

2 . The method of claim 1 , wherein the power loss density for each voxel in the target volume is determined using the formula L=½ σ |E| 2 , where σ is the conductivity of the 3D model at the voxel and |E| is the electric field intensity at the voxel.

3 . The method of claim 1 , wherein the at least one image of the portion comprises an MRI image of the portion.

4 . The method of claim 1 , wherein the given frequency is between 100 kHz and 300 kHz.

5 . A method of planning a treatment using alternating electric fields at a given frequency in a portion of a subject's body, the method comprising the steps of:

(a) obtaining at least one image of the portion;

(b) generating, based on the obtained at least one image, a 3D model of electrical conductivity or resistivity at the given frequency within the portion;

(c) identifying a target volume within the 3D model, the target volume including a plurality of voxels;

(d) adding a first set of model electrodes to the 3D model, with the first set of model electrodes positioned at a first set of locations with respect to the 3D model; and

(e) determining, for each of the voxels in the target volume, a power loss density that will be present when the first set of model electrodes positioned at the first set of locations is used to impose an alternating electric field in the target volume,

wherein step (e) comprises (i) determining, for each of the voxels in the target volume, an electric field intensity that will be present when a respective set of model electrodes positioned at a respective set of locations is used to impose an alternating electric field in the target volume, and (ii) determining a respective power loss density for each voxel in the target volume based on the resistivity of the 3D model at the voxel and the electric field intensity at the voxel.

6 . The method of claim 5 , wherein the at least one image of the portion comprises an MRI image of the portion.

7 . The method of claim 5 , wherein the given frequency is between 100 kHz and 300 kHz.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 069149/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: NAVEH, ARIEL; LEVI, SHAY
To: NOVOCURE GMBH
Reel/Frame 069149/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2024
From: BOMZON, ZEEV; HERSHKOVICH, HADAS SARA; URMAN, NOA
To: NOVOCURE LIMITED
Reel/Frame 069149/0181 →
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2024
From: NAVEH, ARIEL; LEVI, SHAY
To: NOVOCURE GMBH
Reel/Frame 066303/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2024
From: BOMZON, ZEEV; HERSHKOVICH, HADAS SARA; URMAN, NOA
To: NOVOCURE LIMITED
Reel/Frame 066296/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2024
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 066296/0232 →
Continuity (5)
Continuation 16515311 · Jul 18, 2019
Provisional Application 62833983 · Apr 15, 2019
Provisional Application 62754901 · Nov 2, 2018
Provisional Application 62700080 · Jul 18, 2018
Related Publication 20240238588A1 · Jul 18, 2024
References Cited (68)
US 6868289B2 · Palti · 2005 [cited by applicant]
US 7016725B2 · Palti · 2006 [cited by applicant]
US 7089054B2 · Palti · 2006 [cited by applicant]
US 7136699B2 · Palti · 2006 [cited by applicant]
US 7146210B2 · Palti · 2006 [cited by applicant]
US 7333852B2 · Palti · 2008 [cited by applicant]
US 7467011B2 · Palti · 2008 [cited by applicant]
US 7519420B2 · Palti · 2009 [cited by applicant]
US 7565205B2 · Palti · 2009 [cited by applicant]
US 7565206B2 · Palti · 2009 [cited by applicant]
US 7599745B2 · Palti · 2009 [cited by applicant]
US 7599746B2 · Palti · 2009 [cited by applicant]
US 7706890B2 · Palti · 2010 [cited by applicant]
US 7715921B2 · Palti · 2010 [cited by applicant]
US 7805201B2 · Palti · 2010 [cited by applicant]
US 7890183B2 · Palti et al. · 2011 [cited by applicant]
US 7912540B2 · Palti · 2011 [cited by applicant]
US 7917227B2 · Palti · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8027738B2 · Palti · 2011 [cited by applicant]
US 8170684B2 · Palti · 2012 [cited by applicant]
US 8175698B2 · Palti et al. · 2012 [cited by applicant]
US 8229555B2 · Palti · 2012 [cited by applicant]
US RE43618E · Palti · 2012 [cited by applicant]
US 8244345B2 · Palti · 2012 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8447395B2 · Palti et al. · 2013 [cited by applicant]
US 8447396B2 · Palti et al. · 2013 [cited by applicant]
US 8465533B2 · Palti · 2013 [cited by applicant]
US 8706261B2 · Palti · 2014 [cited by applicant]
US 8715203B2 · Palti · 2014 [cited by applicant]
US 8718756B2 · Palti · 2014 [cited by applicant]
US 8764675B2 · Palti · 2014 [cited by applicant]
US 9023090B2 · Palti · 2015 [cited by applicant]
US 9023091B2 · Palti · 2015 [cited by applicant]
US 9039674B2 · Palti et al. · 2015 [cited by applicant]
US 9056203B2 · Palti et al. · 2015 [cited by applicant]
US 9440068B2 · Palti et al. · 2016 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9750934B2 · Palti et al. · 2017 [cited by applicant]
US 9910453B2 · Wasserman et al. · 2018 [cited by applicant]
US 10188851B2 · Wenger et al. · 2019 [cited by applicant]
US 10441776B2 · Kirson et al. · 2019 [cited by applicant]
US 10694972B2 · Davalos · 2020 [cited by examiner]
US 11232853B2 · Schieke · 2022 [cited by examiner]
US 20030191506A1 · Shloznikov · 2003 [cited by applicant]
US 20160055304A1 · Russell · 2016 [cited by examiner]
US 20170120041A1 · Wenger · 2017 [cited by examiner]
US 20170215939A1 · Palti et al. · 2017 [cited by applicant]
US 20170281934A1 · Giladi et al. · 2017 [cited by applicant]
US 20170340384A1 · Deem · 2017 [cited by examiner]
US 20180001075A1 · Kirson et al. · 2018 [cited by applicant]
US 20180008708A1 · Giladi et al. · 2018 [cited by applicant]
US 20180050200A1 · Wasserman et al. · 2018 [cited by applicant]
US 20180153437A1 · Schwartz · 2018 [cited by examiner]
US 20180160933A1 · Urman et al. · 2018 [cited by applicant]
US 20180202991A1 · Giladi et al. · 2018 [cited by applicant]
US 20190117956A1 · Wenger et al. · 2019 [cited by applicant]
US 20190298982A1 · Story et al. · 2019 [cited by applicant]
US 20190307781A1 · Krex et al. · 2019 [cited by applicant]
US 20190308016A1 · Wenger et al. · 2019 [cited by applicant]
US 20200001069A1 · Kirson et al. · 2020 [cited by applicant]
US 20200009376A1 · Chang et al. · 2020 [cited by applicant]
US 20200009377A1 · Chang et al. · 2020 [cited by applicant]
US 20200016067A1 · Gotlib et al. · 2020 [cited by applicant]
US 20200016399A1 · Kaynan et al. · 2020 [cited by applicant]
WO 2011047387A2 · 2011 [cited by applicant]
International Search Report and Written Opinion issued in application No. PCT/IB2019/056181 dated Jan. 8, 2020. [cited by applicant]